1.Application of prospective risk nursing measures in reducing the occurrence of postoperative local hematoma at femoral artery puncture site
Danqing QI ; Jirong YAO ; Hanping DU ; Xue ZHANG ; Yaping BO ; Hong TANG
Journal of Interventional Radiology 2014;(6):539-541
Objective To discuss the application of prospective risk nursing measures in reducing the occurrence of postoperative local hematoma at femoral artery puncture site. Methods A total of 605 patients receiving femoral artery puncture for interventional management were collected as the control group , and 322 patients were used as the intervention group. The risk factors causing postoperative local hematoma at femoral artery puncture site in the control group were recorded, and based on which risk estimation survey table was designed. According to risk estimation survey, the prospective intervention measures, including risk assessment, standardization of professional training, individual health education, the improvement of care appliance, etc. were carried out for the patients of the intervention group. The occurrences of postoperative local hematoma at femoral artery puncture site were recorded and the results were compared between the two groups. Results No statistically significant differences in demographic and clinical data existed between the two groups. However, the incidence of hematoma in the intervention group was significantly lower than that in the control group (χ2 = 4.652, P < 0.05), although the difference in the severity of hematoma was not significant between the two groups. Conclusion The use of prospective risk nursing measures can effectively reduce the incidence of postoperative hematoma at femoral artery puncture site.
2.Cytogenetic abnormalities detected by fluorescence in situ hybridization panel in chronic lymphocytic leukemia
Yi YING ; Xiaoyan CHEN ; Qinghua DU ; Hanping WANG ; Jianjin XIE ; Xiaowei CHEN
Journal of Leukemia & Lymphoma 2014;23(7):416-419
Objective To investigate the significance of fluorescence in situ hybridization (FISH) panel in detecting cytogenetic abnormalities in patients with chronic lymphocytic leukemia (CLL).Methods A panel of FISH probes [D13S25 (13q14.3),RB1 (13q14),ATM(1 1q22.3),CSP12(12p1 1.1-12q1 1.1) and p53 (17p13.1)] were performed in 21 cases with CLL.The cytogenetic features in correlation with clinical manifestation,other laboratory tests and prognosis were analyzed.Results Cytogenetic abnormalities were found in 13 of 21 patients with CLL (61.90 %).The most frequent abnormality was del(13q14) (42.86 %),followed by trisomy 12 (14.29 %),del(11q22) (9.52 %) and del(17p13) (9.52 %).There was no significant relationship among cytogenetic abnormalities and sex,binet stages,expression of CD38,level of lactate dehydrogenase.Conclusion FISH with probe panel is a rapid,sensitive and accurate technique for detection of cytogenetic abnormalities in patients with CLL.
3.Chinese expert consensus on the management of immune-related adverse events of hepato-cellular carcinoma treated with immune checkpoint inhibitors (2021 edition)
Guoming SHI ; Xiaoyong HUANG ; Zhenggang REN ; Yi CHEN ; Leilei CHENG ; Shisuo DU ; Yi FANG ; Ningling GE ; Aimin LI ; Su LI ; Xiaomu LI ; Qian LU ; Pinxiang LU ; Jianfang SUN ; Hanping WANG ; Lai WEI ; Li XU ; Guohuan YANG ; Zhaochong ZENG ; Lan ZHANG ; Li ZHANG ; Haitao ZHAO ; Ling ZHAO ; Ming ZHAO ; Aiping ZHOU ; Rongle LIU ; Xinhui LIU ; Jiaming WU ; Ying ZHANG ; Jia FAN ; Jian ZHOU
Chinese Journal of Digestive Surgery 2021;20(12):1241-1258
The clinical application of immune checkpoint inhibitors (ICIs) has significantly improved the prognosis of hepatocellular carcinoma (HCC) patients. With the widespread applica-tion of ICIs in HCC, the management of immune-related adverse events (irAE) gained more and more attention. However, the complicated disease characteristics and various combination therapies in HCC throw out challenges to irAE management. Therefore, the editorial board of the 'Chinese expert consensus on the management of immune-related adverse events of hepatocellular carcinoma treated with immune checkpoint inhibitors (2021 edition)' organizes multidisciplinary experts to discuss and formulate this consensus. The consensus focuses on issues related to HCC irAE manage-ment, and puts forward suggestions, in order to improve standardized and safety clinical medication, so as to maximize the benefits of immunotherapy for patients.